Is MK-677 (Ibutamoren) Legal in Michigan? A Women's Health Guide to Safe, Legal Access

What Exactly Is MK-677 (Ibutamoren)?

MK-677, sold under the research name Ibutamoren, is a non-peptide, orally active growth hormone secretagogue. It mimics ghrelin and binds to the ghrelin receptor (GHSR-1a), signaling the pituitary to release growth hormone (GH) and subsequently raising insulin-like growth factor 1 (IGF-1). Unlike injectable GH or peptides such as sermorelin or CJC-1295, MK-677 is taken by mouth, which is part of why it has attracted so much consumer interest.

It is not a peptide in the strict molecular sense. It is a small-molecule drug compound. That distinction matters legally and clinically, as you will see below.

Typical doses studied in published trials have ranged from 10 mg to 25 mg daily, taken orally. The compound has a half-life of approximately 24 hours, allowing once-daily dosing.

What MK-677 Is Not

MK-677 is not FDA-approved for any indication. It is not a scheduled controlled substance under federal law (not a DEA Schedule I-V substance). It is also not the same as SARMs, though it is frequently marketed alongside them. These distinctions create its peculiar legal position.

Why Women Are Searching for It

Women in perimenopause and post-menopause experience significant GH pulse reduction alongside estrogen decline. Women with hypothalamic amenorrhea, low muscle mass related to eating disorder recovery, or female-pattern sarcopenia are also drawn to this compound. Those concerns are real and deserve serious clinical attention, even if MK-677 itself is not an approved answer.

The Federal Legal Framework: What Governs MK-677 in Every U.S. State

Federal law sets the floor for MK-677 access, and Michigan cannot override it. Understanding the federal picture first is essential.

FDA Drug Status

MK-677 has never received FDA approval as a pharmaceutical drug. A clinical development program was pursued by Merck and later Lumos Networks under the name ibutamoren for growth hormone deficiency and Alzheimer's disease, but no New Drug Application (NDA) was approved. Because it has been studied under an Investigational New Drug (IND) application, the FDA considers it to have been investigated as a new drug, which creates a specific legal barrier to compounding.

The FDA Bulk Drug Substances List (503A and 503B)

This is the most important legal concept for your access question.

Under the Drug Quality and Security Act (DQSA) of 2013, compounding pharmacies that operate under Section 503A (patient-specific) or Section 503B (outsourcing facilities) may only compound using bulk drug substances that appear on FDA-approved lists, or that are components of FDA-approved drugs.

The FDA maintains a "Bulk Drug Substances Nominated for Use in Compounding" list with three categories:

• Category 1: Nominated and under active evaluation.
• Category 2: Nominated but placed on a list of substances that raise significant safety concerns or are under clinical investigation as new drugs.
• Category 3: Not yet evaluated.

As of 2025, MK-677 (Ibutamoren) has been nominated for inclusion on the 503A bulks list but has not been approved for compounding use. Because it has been the subject of IND studies, the FDA's position is that it cannot be routinely compounded under 503A or 503B without further review. A compounding pharmacy that compounds and dispenses MK-677 under current FDA policy is operating in non-compliance with federal guidance.

This does not make possession of MK-677 by an individual a federal crime. It means the supply chain for compounded MK-677 sits in contested regulatory territory.

DEA Scheduling

MK-677 is not listed under the Controlled Substances Act as a Schedule I, II, III, IV, or V substance. You cannot be arrested for possession under federal drug law solely because you have MK-677. The legal risk is on the manufacturer and pharmacy side, not the consumer side, though buying from unregulated channels creates its own practical risks.

Michigan State Law: What Applies at the State Level

Michigan does not have a specific statute that schedules or bans MK-677. The Michigan Public Health Code, Act 368 of 1978, governs controlled substances and pharmacy practice in Michigan, and MK-677 does not appear on Michigan's controlled substances schedule as of the date of this article.

Michigan Board of Pharmacy

The Michigan Board of Pharmacy oversees compounding pharmacies operating in Michigan. Michigan compounding pharmacies are required to follow both state pharmacy law and federal USP standards. Because federal FDA guidance limits MK-677 compounding, a Michigan compounding pharmacy that compounds MK-677 for non-research purposes is taking on federal regulatory risk, even if no Michigan-specific statute explicitly bans the act.

Michigan Medical Practice Act

A Michigan-licensed physician, NP, or PA can legally discuss MK-677, order IGF-1 labs, and theoretically write a prescription. The prescription itself is not illegal. The complication is finding a compliant pharmacy willing to fill it under current FDA compounding guidance.

The Honest Bottom Line on Michigan Law

There is no Michigan-specific law that makes MK-677 illegal to possess. The legal complexity lives at the federal compounding level. Do not let any online retailer tell you Michigan has "approved" MK-677 or that it is freely legal, because that overstates the reality. Do not let fear paralyze you either: the legal risk for an individual woman obtaining MK-677 from a licensed U.S. Compounding pharmacy that has chosen to compound it is low. The compliance risk sits with the pharmacy.

How to Access MK-677 in Michigan Through a Legal Pathway

The safest and most legally defensible pathway for a Michigan woman who wants to explore MK-677 follows this framework. No single step can be skipped without increasing your risk of receiving an adulterated or misdosed product.

Step 1: Work With a Michigan-Licensed Clinician

You need a licensed clinician (MD, DO, NP, or PA with prescriptive authority in Michigan) who is knowledgeable about GH axis physiology. This clinician should:

• Review your symptom picture in the context of your life stage (reproductive years, perimenopause, post-menopause).
• Order baseline labs: fasting IGF-1, fasting glucose, HbA1c, prolactin, and a full metabolic panel.
• Discuss whether your goals (muscle preservation, sleep quality, recovery) might be addressed by an FDA-approved alternative first.

Telehealth is legal in Michigan for establishing this relationship, and WomanRx clinicians can conduct this evaluation.

Step 2: Understand What Labs You Need

Before any GH secretagogue, your clinician should establish your baseline IGF-1 level. In a 1997 randomized controlled trial of 65 healthy older adults published in the Journal of Clinical Endocrinology and Metabolism, oral MK-677 at 25 mg daily raised mean IGF-1 by approximately 40% over 12 months. IGF-1 that rises above the age-adjusted upper reference range raises theoretical concerns for tissue proliferation, though no clinical trial has demonstrated a causal link to cancer at standard doses.

For women specifically, your clinician should also check prolactin at baseline. Elevated prolactin can disrupt menstrual cycles and worsen symptoms that resemble low estrogen.

Step 3: Source From a Verified U.S. Compounding Pharmacy

If your clinician writes a prescription, work with a PCAB-accredited or state-board-inspected compounding pharmacy. Ask the pharmacy directly whether their MK-677 undergoes third-party Certificate of Analysis (CoA) testing for potency and purity. A pharmacy that cannot produce a CoA on request is not a safe source.

Do not purchase MK-677 from:

• Overseas websites shipping to Michigan addresses.
• "Research chemical" retailers that disclaim human use.
• Any platform that does not require a prescription.

These sources carry real contamination risk. A 2023 analysis of purchased SARMs and research peptides found that approximately 25% of products tested contained unlisted active compounds or incorrect doses, a finding consistent with earlier FDA sampling programs.

Step 4: Monitor on Therapy

If you proceed, monitoring should include:

• IGF-1 at 6-8 weeks, then every 3 months.
• Fasting glucose (MK-677 can increase insulin resistance, especially at 25 mg doses).
• Prolactin if you develop menstrual irregularity or galactorrhea.
• Blood pressure, given fluid retention risk from GH axis stimulation.

Sex-Specific Physiology: How MK-677 Affects Women Differently

Most published MK-677 trials enrolled predominantly male subjects or older mixed cohorts without sex-stratified results. This is an evidence gap you deserve to know about. Women have been historically under-represented in GH secretagogue trials, and the following information combines limited female-specific data with physiological inference.

GH Pulsatility and Estrogen Status

Women naturally have higher GH pulse amplitude than men of comparable age, driven in part by estrogen. As estrogen declines in perimenopause and post-menopause, GH secretion falls substantially. Estrogen replacement has been shown to partially restore GH secretion in post-menopausal women, which means women on hormone therapy (HT) may have a different baseline GH axis response to MK-677 than women not on HT. Your clinician should factor in your HT status before interpreting IGF-1 results.

Insulin Resistance Risk

MK-677 increases GH, which is a counter-regulatory hormone to insulin. In the 12-month RCT by Nass et al., fasting blood glucose increased modestly in MK-677-treated subjects. Women with PCOS already carry elevated insulin resistance, and adding a GH secretagogue without close metabolic monitoring could worsen glucose control. Women with PCOS who are considering MK-677 should discuss this interaction explicitly with their clinician before starting.

Prolactin Elevation

Ghrelin receptor stimulation can increase prolactin secretion. Elevated prolactin in premenopausal women causes menstrual irregularity, anovulation, and reduced libido, symptoms that can be mistaken for perimenopause. Baseline and on-therapy prolactin checks are non-negotiable for women of reproductive age using MK-677.

Fluid Retention and Blood Pressure

GH-driven sodium retention may cause edema, a side effect that appears more prominently in early therapy. Women with pre-existing hypertension or who are in the late luteal phase of their cycle (when aldosterone is already higher) may notice worsening bloating or blood pressure variability.

Life-Stage Considerations

| Life Stage | Key Consideration | |---|---| | Reproductive years (18-40) | Prolactin monitoring; contraception required; limited fertility data | | Trying to conceive | Contraindicated; stop before attempting conception | | Pregnancy | Contraindicated (see dedicated section below) | | Postpartum / breastfeeding | Contraindicated; unknown lactation transfer | | Perimenopause | GH axis already declining; glucose and prolactin monitoring essential | | Post-menopause | Most studied age group; still limited female-only trial data |

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

MK-677 is contraindicated in pregnancy and breastfeeding. This is not a close call.

Pregnancy

MK-677 has no human pregnancy safety data. Animal reproductive studies have not been conducted under GLP conditions that would satisfy FDA teratogenicity review, because the compound has never been approved. The mechanism of action (GH axis stimulation, IGF-1 elevation) raises theoretical concerns for fetal overgrowth syndromes. GH and IGF-1 play critical roles in placental development and fetal growth regulation.

ACOG's guidance on medications in pregnancy consistently advises against using any non-approved compound without established human safety data. MK-677 clearly meets that standard for avoidance.

If you are trying to conceive, stop MK-677 at least one full washout period (approximately 5 half-lives, roughly 5 days for MK-677 itself, though IGF-1 effects may persist longer) before attempting conception. Discuss exact timing with your clinician.

Contraception Requirement

Because MK-677 has no pregnancy safety data, reliable contraception is required for any woman of reproductive potential who chooses to use it. Your clinician should document a contraception plan as part of any prescribing decision. Barrier methods, hormonal contraception, or an IUD are all acceptable depending on your individual medical history.

Lactation

No data exists on MK-677 transfer into human breast milk. Given that IGF-1 is a biologically active growth factor and that MK-677 is lipophilic (suggesting possible milk transfer), the precautionary position is no use during breastfeeding. This is consistent with the LactMed database standard of requiring evidence of safety before use, not merely absence of evidence of harm.

Female-Relevant Conditions Where MK-677 Is Being Discussed

PCOS

Women with PCOS often have altered GH secretion patterns and elevated IGF-1 activity in ovarian tissue. Adding exogenous GH axis stimulation in this context is theoretically complex. No clinical trial has evaluated MK-677 specifically in women with PCOS. ASRM guidelines on PCOS management do not include MK-677 or any GH secretagogue.

Female-Pattern Sarcopenia and Menopause

Post-menopausal women lose approximately 0.5-1% of skeletal muscle mass per year after age 50, with faster losses in the first years after menopause due to estrogen withdrawal. MK-677's most consistent trial finding is lean mass preservation. The Nass et al. 2008 trial in Annals of Internal Medicine (a 2-year RCT, 65 patients, mean age 65) found that MK-677 25 mg daily preserved lean body mass compared to placebo (net difference approximately 1.1 kg), but the cohort was 60% male and results were not reported separately by sex.

Female Pattern Hair Loss

Elevated IGF-1 may support hair follicle cycling, and some women using MK-677 report hair density improvement. No controlled trial has tested this in women with female-pattern hair loss. This is entirely anecdotal and should not be a primary reason to use the compound.

Osteoporosis

GH and IGF-1 both stimulate osteoblast activity, and MK-677 has shown increases in bone turnover markers in trials. Post-menopausal women with low bone density who cannot tolerate or access bisphosphonates or RANK-L inhibitors may find this mechanistically interesting, but no trial has demonstrated fracture reduction with MK-677 in women. ACOG and The Menopause Society recommend evidence-based therapies (bisphosphonates, denosumab, romosozumab, raloxifene) for osteoporosis, not unapproved compounds.

Who This May Be Right For (and Who It Is Probably Not)

Being honest about fit matters more than promoting any compound.

Women for Whom a Clinical Conversation Makes Sense

• Post-menopausal women with documented low IGF-1, significant sarcopenia, and poor response to resistance training despite adequate protein intake, who are working with a clinician experienced in GH physiology.
• Women with GH deficiency confirmed by stimulation testing (a formal diagnosis that may open access to FDA-approved GH products as a more appropriate first step).
• Women in perimenopause with sleep-architecture disruption and low-normal IGF-1, as MK-677 reliably increases REM and slow-wave sleep in published trials (though, again, limited female-specific data exists).

Women Who Should Avoid MK-677

• Anyone pregnant, trying to conceive, or breastfeeding. Full stop.
• Women with active or prior hormone-receptor-positive breast cancer, given theoretical IGF-1 pathway concerns.
• Women with type 2 diabetes or pre-diabetes, given glucose-raising effects without close monitoring.
• Women with PCOS who have elevated fasting insulin without metabolic stabilization.
• Women with a history of acromegaly or IGF-1 levels already at the upper range of normal.
• Anyone planning to buy from an unregulated online source, because the risk of receiving an inaccurately dosed or contaminated product outweighs any potential benefit.

Alternatives Worth Discussing With Your Clinician

If your underlying goals are muscle preservation, bone support, sleep quality, or metabolic health, several FDA-approved or better-studied options exist:

• Sermorelin: A GHRH analogue available through compounding. More established compounding pathway than MK-677. Still requires a prescription.
• Tesamorelin: FDA-approved for HIV-associated lipodystrophy; off-label GH secretagogue use is being studied.
• FDA-approved recombinant GH (somatropin): Indicated for adult GH deficiency with proper stimulation-test diagnosis.
• Hormone therapy: For perimenopausal and post-menopausal women, estradiol-based HT has documented effects on GH pulsatility and lean mass and a far more strong safety dataset in women.
• Resistance training plus adequate leucine-containing protein: The most evidence-supported intervention for sarcopenia in women at any life stage, with a 2022 meta-analysis in JAMA Network Open showing significant lean mass benefit from progressive resistance training in post-menopausal women.

Your clinician should work through these options before MK-677 is considered.